research Oncogenes and morphogens: intricacies of targeted therapy in cutaneous basal cell carcinoma
Targeted therapy for skin cancer is complex due to the role of the hedgehog pathway in both cancer and hair growth.
Search
for
Sort by
Research
360-390 / 1000+ results 
research 860 Understanding cellular & molecular responses in the treatment of pediatric lymphatic anomalies
Sirolimus and propranolol may reduce abnormal cell growth and improve lymphatic malformations in children.
research Thrombospondin-1 Plays a Critical Role in the Induction of Hair Follicle Involution and Vascular Regression During the Catagen Phase
Thrombospondin-1 is crucial for hair follicle regression and reduced blood vessel growth during the catagen phase.
research Modern endovascular and aesthetic surgery techniques to treat arteriovenous malformations of the scalp: case illustration
New techniques for treating scalp blood vessel malformations are effective and can have good cosmetic results.
research 1726: Risk Decrease of Intra-Operative Bleeding During TURP with the Uptake of Finasteride: Evaluation of VEGF and CD34
Finasteride reduces bleeding risk during prostate surgery.
research Induction of T cell exhaustion by JAK1/3 inhibition in the treatment of alopecia areata
Ifidancitinib, a JAK inhibitor, effectively regrows hair in mice with alopecia by tiring out harmful T cells.
research Drug repurposing: A novel strategy to target cancer stem cells and therapeutic resistance
Repurposing existing drugs and using micronutrients may effectively target cancer stem cells and improve cancer treatment.
research Dermatologic Side Effects of Systemic Targeted Anticancer Therapy
Cancer treatments targeting specific cells often cause skin, hair, and nail problems, affecting patients' lives and requiring careful management.
research Green Nanodrugs: Research Progress and Challenges of Plant-Derived Nanovesicles in Tumor Treatment
Plant-derived nanovesicles show promise in cancer treatment but need standardized preparation.
research Tyrosine Kinase Inhibitors against Cancer: Their Safety in 216 Moroccan Patients
Tyrosine Kinase Inhibitors are effective against cancer but can cause skin, digestive, and blood side effects, including hair loss.
research Non-Steroidal Modulation of the 5-Alpha Reductase Axis: A Dual Therapeutic Strategy for Prostatic Chemoprevention and Androgenetic Alopecia
LX-38 is a safer drug option for treating prostate issues and hair loss without hormonal side effects.
research Minimally Invasive Non-Surgical Therapies for Androgenetic Alopecia: A Narrative Review of Clinical Evidence for Regenerative and Locally Acting Antiandrogen Treatments
Platelet-rich plasma, microneedling with minoxidil, and topical finasteride are promising treatments for hair loss.
research PROTECTION AGAINST CYTOSINE ARABINOSIDE-INDUCED ALOPECIA BY MINOXIDIL IN A RAT ANIMAL MODEL
Minoxidil helps prevent hair loss from chemotherapy in rats.
research Identification of bioactive compounds from thai plant extracts with hair growth promoting activity on human hair dermal papilla cells
Thai plant extracts, especially Avicennia marina, can promote hair growth by inhibiting certain enzymes and boosting growth factors.
research Comparison of the pharmacoeconomic profiles of treatment regimens for field pattern actinic keratoses
Some blood pressure medications are linked to a higher risk of skin cancer.
research The novel drug CS-891 inhibits 5alpha-reductase activity in freshly isolated dermal papilla of human hair follicles.
CS-891 may effectively treat hair loss by blocking enzymes in hair follicles.
research Persistent hair growth over a hemangioma in a patient with alopecia areata: A clue to pathogenesis?
research Androgenetic alopecia; drug safety and therapeutic strategies
Personalized treatment with inhibitors, minoxidil, and laser therapy helps hair loss.
research Androgenetic alopecia: An update
Two drugs, finasteride and minoxidil, are approved for hair loss treatment, but new therapies are being developed.
research EFFECTS OF α-MELANOCYTE-STIMULATING HORMONE AND [8-ARGININE]-VASOTOCIN UPON MELANOGENESIS IN HAIR FOLLICLE MELANOCYTES IN VITRO
α-MSH increases melanin production in moulting hair follicles, while AVT inhibits it.
research Wound healing with topical BRAF inhibitor therapy in a diabetic model suggests tissue regenerative effects
A topical BRAF inhibitor, vemurafenib, can speed up wound healing and promote hair growth, especially in diabetic patients.
research Logic-based modeling and drug repurposing for the prediction of novel therapeutic targets and combination regimens against E2F1-driven melanoma progression
Tadalafil and Finasteride may help treat aggressive melanoma.
research Alopecia and hair repigmentation associated with anti-programmed death-ligand 1 (PD-L1) immunotherapy
research Antiandrogen therapy for androgenetic alopecia
Antiandrogen therapy helps treat genetic hair loss.
research Finasteride blocks progesterone synthesis in MA-10 Leydig tumor cells
research Down‐regulation of Shh in the hair follicles of mice during chemotherapy‐induced hair loss is mediated by the JAK / STAT1 signaling pathway
JAK/STAT1 pathway causes hair loss during chemotherapy by reducing Shh in hair follicles.
research Reduced Prostate Cancer Risk in Patients with Androgenetic Alopecia Using 5-Alpha Reductase Inhibitors: A TriNetX Real-World Cohort Study
Using 5-alpha reductase inhibitors may lower prostate cancer risk in people with androgenetic alopecia.
research Enriching Proteolysis Targeting Chimeras with a Second Modality: When Two Are Better Than One
Adding a second method to PROTACs could improve cancer treatment.
research Data from Tumor Necrosis Factor-α and Interleukin-1 Antagonists Alleviate Inflammatory Skin Changes Associated with Epidermal Growth Factor Receptor Antibody Therapy in Mice
TNFα and interleukin-1 blockers reduce skin inflammation from EGFR antibody therapy.
research Data from Tumor Necrosis Factor-α and Interleukin-1 Antagonists Alleviate Inflammatory Skin Changes Associated with Epidermal Growth Factor Receptor Antibody Therapy in Mice
TNFα and interleukin-1 blockers reduce skin inflammation from EGFR antibody therapy.